Menu

New Resource for Banked iPSCs

Researchers describe hundreds of induced pluripotent stem cell lines from healthy individuals. 

May 11, 2017
Aggie Mika

WIKIMEDIA, CSIRO

                 An international team of scientists has characterized and made available 711 induced pluripotent stem cell (iPSC) lines from 301 healthy individuals, according to a paper published today (May 10) in Nature. The researchers also investigated sources of variability within these banked cell lines, a common characteristic of existing iPSC lines that can pose challenges for researchers.  

“Many other efforts to create stem cells focus on rare diseases. In our study, stem cells have been produced from hundreds of healthy volunteers to study common genetic variation,” said Fiona Watt, lead author and Director of the Centre for Stem Cells and Regenerative Medicine at King's College London, in a press release

Because the researchers derived more than one cell line from individual participants, they were able to demonstrate that “up to 46 percent of the differences we saw in iPS cells were due to differences between individuals,” Watt said, indicating that genetic differences between people drives variation in the cells’ phenotypes. 

“These data will allow researchers to put disease variations in context with healthy people,” she added.

See “Banking on iPSCs

This endeavor was part of the Human Induced Pluripotent Stem Cell Initiative, which is described by the authors in the study as “a large, high-quality, open-access reference panel of human iPSC lines”

“This resource is a stepping stone for researchers to make better cell models of many diseases, because they can study disease risk in many cell types, including those that are normally inaccessible,” said Daniel Gaffney, a lead author and a geneticist at the Wellcome Trust Sanger Institute. 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!